IL-15 treatment of SIV-infected non-human primates

IL-15 治疗 SIV 感染的非人灵长类动物

基本信息

  • 批准号:
    7149982
  • 负责人:
  • 金额:
    $ 55.54万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2004
  • 资助国家:
    美国
  • 起止时间:
    2004-12-01 至 2008-11-30
  • 项目状态:
    已结题

项目摘要

Cytotoxic CD8+ T cell (CTL) responses play a critical protective role against HIV virus. A number of studies, however, have indicated that HIV-specific CD8+ T cells may be functionally impaired. Furthermore, we have demonstrated that HIV-specific CD8+ T cells exhibit increased susceptibility to undergo CD95/Fas-mediated apoptosis and HIV-infected macrophages can kill these cells. This apoptosis of HIV-specific CD8+ T cells therefore may impair their ability to function as serial killers. Augmenting the effector function and the survival of HIV-specific CD8+ T cells would greatly enhance the efficiency of these cells to control or clear HIV virus. Interleukin 15 (IL-15) is a pluripotent cytokine that we have shown potently inhibits CD95/Fas-mediated apoptosis of HIV-specific CD8+ T cells and upregulates the anti-apoptotic Bcl-2 and Bcl-xL molecules in these cells. Furthermore IL-15 enhances their cytotoxic activity and IFNgamma production. SIV-specific CD8+ T cells from SIV-infected rhesus macaques also show increased sensitivity to CD95/Fas-mediated apoptosis and IL-15 potently inhibits this apoptosis and upregulates Bcl-2 and Bcl-xL molecules. Based on these observations, we recently performed a short pilot study in chronically SIV-infected cynomolgus macaques to investigate the potentially beneficial effect of IL-15 treatment in vivo. In vivo treatment with IL-15 significantly increased peripheral blood CD8-t- T cell and NK cell numbers by more than 2-fold. This increase was mainly due to proliferation of CD8+ T cells, as proliferating Ki67^ CD8+ T cells increased with treatment. The expanded CD8+ T cells were of the CD45RA- CD62L- and CD45RA+ CD62L- effector memory phenotype. We hypothesize that IL-15 treatment in vivo can enhance cytotoxic CD8+ T cells immunity against SIV and enhance antiviral immunity. We propose to examine the effect of in vivo treatment with recombinant simian IL-15 on primary and chronic SIV infection of rhesus macaques. Synergy with ART treatment will also be evaluated in chronic infection studies. Viral load, immunological changes, apoptosis and Bcl-2/Bcl-xL molecule expression will be evaluated. In particular the effect of in vivo IL-15 treatment on SIV-specific CTL response will be investigated. The studies in this proposal are novel and will provide valuable information on the potential therapeutic value of IL-15. Information yielded from these studies may prove useful for the design of novel therapeutic strategies against HIV infection and other viral infections.
细胞毒性CD 8 + T细胞(CTL)应答在抗HIV病毒中起关键的保护作用。然而,许多研究表明,HIV特异性CD 8 + T细胞可能功能受损。此外,我们已经证明,HIV特异性CD 8 + T细胞表现出增加的易感性进行CD 95/Fas介导的凋亡和HIV感染的巨噬细胞可以杀死这些细胞。因此,HIV特异性CD 8 + T细胞的凋亡可能会削弱其作为连环杀手的能力。增强HIV特异性CD 8 + T细胞的效应子功能和存活将大大提高这些细胞控制或清除HIV病毒的效率。白细胞介素15(IL-15)是一种多能性细胞因子,我们已经显示其有效地抑制HIV特异性CD 8 + T细胞的CD 95/Fas介导的凋亡,并上调这些细胞中的抗凋亡Bcl-2和Bcl-xL分子。此外,IL-15增强它们的细胞毒性活性和IFN γ产生。来自SIV感染的恒河猴的SIV特异性CD 8 + T细胞也显示出对CD 95/Fas介导的凋亡的敏感性增加,IL-15有效地抑制这种凋亡并上调Bcl-2和Bcl-xL分子。基于这些观察结果,我们最近在慢性SIV感染的食蟹猴中进行了一项简短的初步研究,以研究IL-15治疗在体内的潜在有益作用。用IL-15的体内治疗使外周血CD 8-t-T细胞和NK细胞数量显著增加超过2倍。这种增加主要是由于CD 8 + T细胞的增殖,因为增殖的Ki 67 + CD 8 + T细胞随着治疗而增加。扩增的CD 8 + T细胞具有CD 45 RA-CD 62 L-和CD 45 RA + CD 62 L-效应记忆表型。我们推测IL-15在体内治疗可以增强细胞毒性CD 8 + T细胞对SIV的免疫,并增强抗病毒免疫。我们建议检查重组猴IL-15体内治疗对恒河猴原发性和慢性SIV感染的影响。还将在慢性感染研究中评价与ART治疗的协同作用。将评价病毒载量、免疫学变化、细胞凋亡和Bcl-2/Bcl-xL分子表达。具体地,将研究体内IL-15处理对SIV特异性CTL应答的影响。该提案中的研究是新颖的,并将提供有关IL-15潜在治疗价值的有价值的信息。从这些研究中获得的信息可能会被证明是有用的设计新的治疗策略,对艾滋病毒感染和其他病毒感染。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

PETER D KATSIKIS其他文献

PETER D KATSIKIS的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('PETER D KATSIKIS', 18)}}的其他基金

Phosphorothioate Oligonucleotides as Microbicides against HIV Transmission
硫代磷酸酯寡核苷酸作为抗 HIV 传播的杀菌剂
  • 批准号:
    8516438
  • 财政年份:
    2010
  • 资助金额:
    $ 55.54万
  • 项目类别:
Phosphorothioate Oligonucleotides as Microbicides against HIV Transmission
硫代磷酸酯寡核苷酸作为抗 HIV 传播的杀菌剂
  • 批准号:
    8695278
  • 财政年份:
    2010
  • 资助金额:
    $ 55.54万
  • 项目类别:
Phosphorothioate Oligonucleotides as Microbicides against HIV Transmission
硫代磷酸酯寡核苷酸作为抗 HIV 传播的杀菌剂
  • 批准号:
    8062112
  • 财政年份:
    2010
  • 资助金额:
    $ 55.54万
  • 项目类别:
Phosphorothioate Oligonucleotides as Microbicides against HIV Transmission
硫代磷酸酯寡核苷酸作为抗 HIV 传播的杀菌剂
  • 批准号:
    7884776
  • 财政年份:
    2010
  • 资助金额:
    $ 55.54万
  • 项目类别:
Phosphorothioate Oligonucleotides as Microbicides against HIV Transmission
硫代磷酸酯寡核苷酸作为抗 HIV 传播的杀菌剂
  • 批准号:
    8482137
  • 财政年份:
    2010
  • 资助金额:
    $ 55.54万
  • 项目类别:
Dendritic cell regulation of CD8+ T cell responses
CD8 T 细胞反应的树突状细胞调节
  • 批准号:
    6964213
  • 财政年份:
    2005
  • 资助金额:
    $ 55.54万
  • 项目类别:
Dendritic cell regulation of CD8+ T cell responses
CD8 T 细胞反应的树突状细胞调节
  • 批准号:
    7084539
  • 财政年份:
    2005
  • 资助金额:
    $ 55.54万
  • 项目类别:
Dendritic cell regulation of CD8+ T cell responses
CD8 T 细胞反应的树突状细胞调节
  • 批准号:
    7386756
  • 财政年份:
    2005
  • 资助金额:
    $ 55.54万
  • 项目类别:
Dendritic cell regulation of CD8+ T cell responses
CD8 T 细胞反应的树突状细胞调节
  • 批准号:
    7211374
  • 财政年份:
    2005
  • 资助金额:
    $ 55.54万
  • 项目类别:
Dendritic cell regulation of CD8+ T cell responses
CD8 T 细胞反应的树突状细胞调节
  • 批准号:
    7587430
  • 财政年份:
    2005
  • 资助金额:
    $ 55.54万
  • 项目类别:

相似海外基金

The earliest exploration of land by animals: from trace fossils to numerical analyses
动物对陆地的最早探索:从痕迹化石到数值分析
  • 批准号:
    EP/Z000920/1
  • 财政年份:
    2025
  • 资助金额:
    $ 55.54万
  • 项目类别:
    Fellowship
Animals and geopolitics in South Asian borderlands
南亚边境地区的动物和地缘政治
  • 批准号:
    FT230100276
  • 财政年份:
    2024
  • 资助金额:
    $ 55.54万
  • 项目类别:
    ARC Future Fellowships
The function of the RNA methylome in animals
RNA甲基化组在动物中的功能
  • 批准号:
    MR/X024261/1
  • 财政年份:
    2024
  • 资助金额:
    $ 55.54万
  • 项目类别:
    Fellowship
Ecological and phylogenomic insights into infectious diseases in animals
对动物传染病的生态学和系统发育学见解
  • 批准号:
    DE240100388
  • 财政年份:
    2024
  • 资助金额:
    $ 55.54万
  • 项目类别:
    Discovery Early Career Researcher Award
Zootropolis: Multi-species archaeological, ecological and historical approaches to animals in Medieval urban Scotland
Zootropolis:苏格兰中世纪城市动物的多物种考古、生态和历史方法
  • 批准号:
    2889694
  • 财政年份:
    2023
  • 资助金额:
    $ 55.54万
  • 项目类别:
    Studentship
Using novel modelling approaches to investigate the evolution of symmetry in early animals.
使用新颖的建模方法来研究早期动物的对称性进化。
  • 批准号:
    2842926
  • 财政年份:
    2023
  • 资助金额:
    $ 55.54万
  • 项目类别:
    Studentship
Study of human late fetal lung tissue and 3D in vitro organoids to replace and reduce animals in lung developmental research
研究人类晚期胎儿肺组织和 3D 体外类器官在肺发育研究中替代和减少动物
  • 批准号:
    NC/X001644/1
  • 财政年份:
    2023
  • 资助金额:
    $ 55.54万
  • 项目类别:
    Training Grant
RUI: Unilateral Lasing in Underwater Animals
RUI:水下动物的单侧激光攻击
  • 批准号:
    2337595
  • 财政年份:
    2023
  • 资助金额:
    $ 55.54万
  • 项目类别:
    Continuing Grant
RUI:OSIB:The effects of high disease risk on uninfected animals
RUI:OSIB:高疾病风险对未感染动物的影响
  • 批准号:
    2232190
  • 财政年份:
    2023
  • 资助金额:
    $ 55.54万
  • 项目类别:
    Continuing Grant
A method for identifying taxonomy of plants and animals in metagenomic samples
一种识别宏基因组样本中植物和动物分类的方法
  • 批准号:
    23K17514
  • 财政年份:
    2023
  • 资助金额:
    $ 55.54万
  • 项目类别:
    Grant-in-Aid for Challenging Research (Exploratory)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了